Viimeisin päivitys :
26/03/2024
Syöpälääke   Methotrexate sodium  
Injektioneste
Stabilius liuoksessa Stabilius seoksissa Tekijät, jotka vaikuttavat stabiliuteen Yhteensopivuus Antotapa Viitteet Pdf
   Kemiallinen rakenne  

Kauppanimi   Kauppanimi     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Abitrexate Etelä-Afrikka
Antifolan Romania
Artrait Argentiina
Bendatrexat Saksa
Biometrox Brasilia
Ebetrex Sveitsi
Ebetrexate Itävalta
Emthexat Turkki
Emthexate Belgia, Espanja, Etelä-Afrikka, Hollanti
Ledertrexate Belgia, Luxemburg, Marokko, Ranska
Maxtrex Iso-Britannia
Metex Norja, Saksa
Methoblastin Etelä-Afrikka
Methotrexamed Saksa
Methotrexate Ranska
Metoject Chile, Espanja, Hollanti, Iso-Britannia, Ranska, Ruotsi, Suomi, Sveitsi, Tanska
Metotrexato Chile
Trexan Suomi
Trexat Saksa
Viitteet   Injektioneste   Viitteet : Methotrexate sodium  
Tyyppi Julkaisu
3 Lehti Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
31 Lehti Zhang Y, Xu QA, Trissel LA, Gilbert DL.
Physical and chemical stability of methotrexate sodium, cytarabine, and hydrocortisone sodium succinate in Elliott’s B solution.
Hosp Pharm 1996 ; 31: 965-970.
57 Lehti Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 Lehti Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Lehti Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
85 Lehti Trissel LA, Bready BB.
Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 1716-1719.
91 Lehti Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
99 Lehti Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
110 Lehti Vincke BJ, Verstraeten AE, El Eini DID, Mc Carthy TM.
Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers.
Int J Pharm 1989 ; 54: 181-189.
145 Lehti Lorillon P, Corbel JC, Mordelet MF, Basle B, Guesnier LR.
Photosensibility of 5-fluorouracile and methotrexate in translucent or opaque perfusers.
J Pharm Clin 1992 ; 11: 285-295.
150 Lehti Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
162 Lehti Benaji B, Dine T, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Gressier B, Cazin M, Cazin JC.
Compatibility study of methotrexate with PVC bags after repackaging into two types of infusion admixtures.
Int J Pharm 1994 ; 105: 83-87.
169 Lehti Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
184 Lehti Stewart JT, Warren FW, King DT, Fox JL.
Stability of ondansetron hydrochloride and five antineoplasic medications.
Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244 Lehti Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Lehti Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Lehti Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300 Lehti Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Lehti Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Lehti Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
331 Lehti Marquardt ED.
Visual compatibility of hydroxyzine hydrochloride with various antineoplasic agents.
Am J Hosp Pharm 1988 ; 45: 2127.
334 Lehti Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Lehti Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
431 Lehti McRae MP, King JC.
Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures.
Am J Hosp Pharm 1975 ; 33: 1010-1013.
491 Lehti Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184.
492 Lehti Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
739 Lehti Cradock JC, Kleinmann LM, Rahman A.
Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate.
Am J Hosp Pharm 1978 ; 35: 402-406.
763 Lehti Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH.
Drug precipitation within IV tubing : A potential hazard of chemotherapy administration.
Cancer Treat Rep 1985 ; 69: 1325-1326.
859 Lehti Karlsen J, Thonnesen HH, Olsen IR, Sollien AH, Skobba TJ.
Stability of cytotoxic intravenous solutions subjected to freeze-thaw treatment.
Nor Pharm Acta 1983 ; 45: 61-67.
905 Lehti Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Lehti Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
978 Lehti Dick DM, Woloschuk DMM.
Methotrexate and cytarabine for intrathecal administration.
Can J Hosp Pharm 1994 ; 47: 147.
1021 Lehti Dyvik O, Grislingaas AL, Tonnesen HH, Karlsen J.
Methotrexate in solutions - A stability test for the hospital pharmacy.
J Clin Hosp Pharm 1986 ; 11: 343-348.
1028 Lehti Cheung YW, Vishnuvajjala BR, Flora KP.
Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures.
Am J Hosp Pharm 1984 ; 41: 1802-1806.
1088 Lehti Johnston A, McKenzie MA, Krasnow SH, Hood MA, Cohen MH.
Drug trapping in intravenous infusion side arms.
JAMA 1984 ; 252: 2392.
1155 Lehti Wright MP, Newton JM.
Stability of methotrexate injection in prefilled plastic disposable syringes.
Int J Pharm 1988 ; 45: 237-244.
1158 Lehti McElnay JC, Elliott DS, Cartwright-Shamoon J, D?Arcy PF.
Stability of methotrexate and vinblastine in burette administration sets.
Int J Pharm 1988 ; 47: 239-247.
1410 Lehti Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Lehti Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Lehti Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1469 Lehti Jacolot A, Arnaud P, Lecompte D, Alamercery S, Caroff E, Naveau C, Guillot T, Bousselet M, Brion F.
Stability and compatibility of 2.5 mg/ml methotrexate solution in plastic syringes over 7 days.
Int J Pharm 1996 ; 128: 283-286.
1501 Lehti Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1520 Laboratorio Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1625 Lehti Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1661 Lehti Trissel LA, King KM, Zhang Y, Wood AM.
Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott’s B Solution for intrathecal use.
J Oncol Pharm Practice 2002 ; 8: 27-32.
1662 Lehti Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1925 Lehti Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
2262 Lehti Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3275 Lehti D'Hondt M, Vangheluwe E, Van Dorpe S, Boonen J, Bauters T, Pelfrene B, Vandenbroucke J, Robays H, De Spiegeleer B
Stability of extemporaneously prepared cytarabine, methotrexate sodium, and methylprednisolone sodium succinate
Am J Health-Syst Pharm 2012 ; 69: 232-240.
3474 Laboratorio Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3580 Laboratorio Cytarabine Accord - Résumé des caractéristiques du produit
Accord Healthcare France 2016
3637 Laboratorio Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014
3670 Lehti Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3731 Lehti Chatterji D.C, Gallelli J.F.
Thermal and photolytic decomposition of methotrexate in aqueous solutions.
J Pharm Sci 1978 ; 67, 4: 526-530.
3980 Lehti Nissen K.B, Jorgensen L.B, Berg D.L, Andersen G.
Stability study of methotrexate in 0.9% sodium chloride injection and 5% dextrose injection with limit tests for impurities.
Am J Health-Syst Pharm 2017 ; 74,9: e211-e223
4154 Laboratorio Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018
4578 Opinnäytetyö Respaud R.
Etude de stabilité de médicaments anticancéreux injectables : apports analytiques et pharmaceutiques
2011
4641 Lehti Zanon D, Selmin F, Centin G, Maximova N, Casiraghi A, Minghetti P.
Stability of high concentrated triple intrathecal therapy for pediatrics and mitigation strategies.
Eur J Pharm Sci 2021 ;167: 106039.

  Mentions Légales